APA

Baruch A., Mosesova S., Davis J. D., Budha N., Vilimovskij A., Kahn R., Peng K., Cowan K. J., Harris L. P., Gelzleichter T., Lehrer J., Davis J. C. & Tingley W. G. (20170809). Effects of RG7652, a Monoclonal Antibody Against PCSK9, on LDL-C, LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or With Established Coronary Heart Disease (from the Phase 2 EQUATOR Study). : The American journal of cardiology.

Chicago

Baruch Amos, Mosesova Sofia, Davis John D, Budha Nageshwar, Vilimovskij Alexandr, Kahn Robert, Peng Kun, Cowan Kyra J, Harris Laura Pascasio, Gelzleichter Thomas, Lehrer Josh, Davis John C and Tingley Whittemore G. 20170809. Effects of RG7652, a Monoclonal Antibody Against PCSK9, on LDL-C, LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or With Established Coronary Heart Disease (from the Phase 2 EQUATOR Study). : The American journal of cardiology.

Harvard

Baruch A., Mosesova S., Davis J. D., Budha N., Vilimovskij A., Kahn R., Peng K., Cowan K. J., Harris L. P., Gelzleichter T., Lehrer J., Davis J. C. and Tingley W. G. (20170809). Effects of RG7652, a Monoclonal Antibody Against PCSK9, on LDL-C, LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or With Established Coronary Heart Disease (from the Phase 2 EQUATOR Study). : The American journal of cardiology.

MLA

Baruch Amos, Mosesova Sofia, Davis John D, Budha Nageshwar, Vilimovskij Alexandr, Kahn Robert, Peng Kun, Cowan Kyra J, Harris Laura Pascasio, Gelzleichter Thomas, Lehrer Josh, Davis John C and Tingley Whittemore G. Effects of RG7652, a Monoclonal Antibody Against PCSK9, on LDL-C, LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or With Established Coronary Heart Disease (from the Phase 2 EQUATOR Study). : The American journal of cardiology. 20170809.